Vyne Therapeutics Inc (VYNE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $30.58 (+17.89%), Market cap $0.02B, 52-week low–high $0.29 ~ $1.77.
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its
Financial statements, price targets, institutional (13F) holdings and related news for Vyne Therapeutics Inc are updated in real time on BlackAll Trade.
Vyne Therapeutics Inc trades at $30.58 (+17.89%). Real-time quotes and charts are available on BlackAll Trade.
Vyne Therapeutics Inc has a market cap of about $0.02B.
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibres